Ultrasensitive Circulating Tumor DNA Improves NSCLC Detection
Ultrasensitive Circulating Tumor DNA improves clinical sensitivity of minimal residual disease in early stage non-small cell lung cancer.
Read More
Meeting Coverage
ALBI Grade, MVI, & Distant Metastases Predict Survival in HCC
HCC survival time is predicted by albumin-bilirubin grade, microvascular invasion, and distant metastases.
Read More
Barriers to Care Delay Costly Multiple Myeloma Treatment
Social determinants of health create barriers that delay access to expensive oral anti-myeloma drugs for people with newly diagnosed multiple myeloma.
Read More
AI and ML Show Promise in Targeting Therapies for Chronic Lymphocytic Leukemia
AI and ML advances chronic lymphocytic leukemia therapies.
Read More
Correlation of Treatment Response with PFS and OS in Patients with R/R CLL or SLL
The following is a summary of “Association between treatment (tx) response and PFS and OS in R/R...
Read More
Analyzing CR as a Surrogate Endpoint for PFS in R/R CLL/SLL
The following is a summary of “Evaluating CR as a surrogate endpoint for PFS in R/R chronic...
Read More
Adjuvant Immunotherapy and Survival Outcomes in Intermediate/Advanced HCC
The following is a summary of “Survival outcomes with adjuvant immunotherapy after hepatic...
Read More
Phosphoproteomics Unveils AB Response in Patients with aHCC
The following is a summary of “Identification of a predictive phosphoproteomic signature of...
Read More
Precision Medicine in HCC: Unveiling Molecular Subtypes through Integrated Multi-Omics Analysis
The following is a summary of “Identification of molecular subtypes for integrated multi-omics...
Read More
Comparing Lenvatinib and Atezolizumab-Bevacizumab in Advanced HCC Treatment
The following is a summary of “Atezolizumab + bevacizumab versus lenvatinib as first-line systemic...
Read More
Study Shows Disparities in Palliative Care Use for Patients With Hepatocellular Carcinoma
Researchers at the 2024 ASCO Annual Meeting found racial and ethnic disparities in palliative care use among patients with advanced hepatocellular carcinoma.
Read More
Fixed-Duration Regimen Substantially Benefits PFS in Patients With CLL/SLL
Fixed duration ibrutinib plus venetoclax benefited survival outcomes in patients with high-risk CLL/SLL over more than 5 years of follow-up.
Read More
Examining Mortality in Patients With Multiple Myeloma and the Role of Infectious Diseases
Investigators examined the changes in mortality rates due to COVID-19, influenza, and pneumonia in patients with MM.
Read More
Survival Outcomes in Early-Stage NSCLC With Rare Mutations
The treatment landscape for non-small cell lung cancer has significantly evolved with the advent of targeted therapies.
Read More
Examining the Link Between Social Determinants of Time and Health to Treatment for NDMM
The following is a summary of “Association between social determinants of health and time to...
Read More
Examining the Link Between Treatment Patterns and Financial Fragility in Multiple Myeloma
The following is a summary of “Association between financial fragility and treatment patterns in...
Read More
Analysis of Palliative Care Accessibility in Patients with Multiple Myeloma
The following is a summary of “Access to palliative care in patients with multiple myeloma in the...
Read More
Insights into Electronic OAM Adherence in Patients with MM: Patterns and Predictors
The following is a summary of “Patterns and predictors of electronically measured oral anticancer...
Read More
Tandem Transplantation’s Impact on RWO in Newly Diagnosed Patients with Multiple Myeloma
The following is a summary of “Real-world outcomes (RWO) with tandem transplantation in patients...
Read More
Exploring Atezolizumab Combination Therapy for NSCLC: J-TAIL-2 Study
The following is a summary of “J-TAIL-2: A prospective observational study of atezolizumab (atezo)...
Read More